Search Results - "Ferrant, Emmanuelle"

Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia by Sharman, Jeff P., Egyed, Miklos, Jurczak, Wojciech, Skarbnik, Alan, Pagel, John M., Flinn, Ian W., Kamdar, Manali, Munir, Talha, Walewska, Renata, Corbett, Gillian, Fogliatto, Laura Maria, Herishanu, Yair, Banerji, Versha, Coutre, Steven, Follows, George, Walker, Patricia, Karlsson, Karin, Ghia, Paolo, Janssens, Ann, Cymbalista, Florence, Woyach, Jennifer A., Ferrant, Emmanuelle, Wierda, William G., Munugalavadla, Veerendra, Yu, Ting, Wang, Min Hui, Byrd, John C.

Get full text

Impact of using leader primers for IGHV mutational status assessment in chronic lymphocytic leukemia by Huet, Sarah, Bouvard, Anne, Ferrant, Emmanuelle, Mosnier, Isabelle, Chabane, Kaddour, Salles, Gilles, Michallet, Anne Sophie, Hayette, Sandrine, Sujobert, Pierre

Get full text

Blinatumomab after R-CHOP bridging therapy for patients with Richter transformation: a phase 2 multicentre trial by Guièze, Romain, Ysebaert, Loïc, Roos-Weil, Damien, Fornecker, Luc-Mathieu, Ferrant, Emmanuelle, Molina, Lysiane, Aurran, Thérèse, Clavert, Aline, de Guibert, Sophie, Michallet, Anne-Sophie, Saad, Alain, Drénou, Bernard, Quittet, Philippe, Hivert, Bénédicte, Laribi, Kamel, Gay, Julie, Quinquenel, Anne, Broseus, Julien, Rouille, Valérie, Schwartz, David, Magnin, Benoit, Lazarian, Grégory, Véronèse, Lauren, de Antonio, Marie, Laurent, Camille, Tournilhac, Olivier, Pereira, Bruno, Feugier, Pierre

“…Richter transformation (RT) is an aggressive lymphoma occurring in patients with chronic lymphocytic leukaemia. Here we investigated the anti-CD3/anti-CD19…”
Get full text

End-of-life management of multiple myeloma patients in the era of CD38 and immunotherapy by Sesques, Pierre, Karlin, Lionel, Massy, Emmanuel, Maarek, Alizée, Aussedat, Guillaume, Lazareth, Anne, Golfier, Camille, Bouafia-Sauvy, Fadhela, Lequeu, Helene, Ghergus, Dana, Safar, Violaine, Ferrant, Emmanuelle, Bachy, Emmanuel, Ghesquières, Hervé, Confavreux, Cyrille B., Demangel, Delphine, Perrial, Emeline, Dumontet, Charles

“…Background In spite of spectacular advances in the treatment of multiple myeloma, a majority of patients will die from this disease or related complications…”
Get full text

Increased rituximab exposure does not improve response and outcome of patients with chronic lymphocytic leukemia after fludarabine, cyclophosphamide, rituximab. A French Innovative Leukemia Organization (FILO) study by Cartron, Guillaume, Letestu, Rémi, Dartigeas, Caroline, Tout, Mira, Mahé, Béatrice, Gagez, Anne-Laure, Ferrant, Emmanuelle, Guiu, Boris, Villemagne, Bruno, Letuan, Phan, Aurran, Thérèse, Orsini-Piocelle, Frédérique, Banos, Anne, Feugier, Pierre, Leblond, Véronique, de Guibert, Sophie, Tournilhac, Olivier, Dupuis, Jehan, Delmer, Alain, Rouillé, Valérie, Ternant, David, Leprêtre, Stéphane

Get full text

Crystal‐storing histiocytosis and Bing‐Neel‐like syndrome revealing a small B‐cell lymphoma with plasmacytic differentiation, presumed to be a marginal zone lymphoma by Lequain, Hippolyte, Gerfaud‐Valentin, Mathieu, Fontaine, Juliette, Ferrant, Emmanuelle, Grumet, Pierre, Jamilloux, Yvan, Traverse‐Glehen, Alexandra, Sève, Pascal

“…Crystal‐storing histiocytosis and Bing‐Neel syndrome are two diseases induced by paraproteins. Herein, we report a rare case of crystal‐storing histiocytosis…”
Get full text

Significant increase in the apparent incidence of essential thrombocythemia related to new WHO diagnostic criteria: a population-based study by Girodon, Francois, Bonicelli, Gilles, Schaeffer, Celine, Mounier, Morgane, Carillo, Serge, Lafon, Ingrid, Carli, Paule Marie, Janoray, Ines, Ferrant, Emmanuelle, Maynadie, Marc

“…1 Laboratoire d’Hématologie, Centre Hospitalier Universitaire (CHU) de Dijon 2 Registre des hémopathies malignes de Côte d’Or, EA 4184 Université de Bourgogne,…”
Get full text

A prospective analysis of the genotypic diversity and dynamics of the Candida albicans colonizing flora in neutropenic patients with de novo acute leukemia by Dalle, Frederic, Lafon, Ingrid, L'Ollivier, Coralie, Ferrant, Emmanuelle, Sicard, Pierre, Labruere, Catherine, Jebrane, Ahmed, Laubriet, Aline, Vagner, Odile, Caillot, Denis, Bonnin, Alain

“…1 Laboratoire de Parasitologie Mycologie, CHU, Hôpital du Bocage, Dijon Cedex; 2 Laboratoire Interaction Muqueuses-Agents Transmissibles, IFR Santé-STIC,…”
Get full text

Low urine osmolarity as a determinant of cisplatin‐induced nephrotoxicity by Polycarpe, Emmanuel, Arnould, Laurent, Schmitt, Elise, Duvillard, Laurence, Ferrant, Emmanuelle, Isambert, Nicolas, Duvillard, Christian, Beltramo, Jean‐Luc, Chevet, Dominique, Chauffert, Bruno

“…Cisplatin is widely used in the treatment of human tumors, but it is a nephrotoxic drug. Early pragmatic clinical trials have shown that cisplatin‐induced…”
Get full text

Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib by Ghez, David, Calleja, Anne, Protin, Caroline, Baron, Marine, Ledoux, Marie-Pierre, Damaj, Gandhi, Dupont, Mathieu, Dreyfus, Brigitte, Ferrant, Emmanuelle, Herbaux, Charles, Laribi, Kamel, Le Calloch, Ronan, Malphettes, Marion, Paul, Franciane, Souchet, Laetitia, Truchan-Graczyk, Malgorzata, Delavigne, Karen, Dartigeas, Caroline, Ysebaert, Loïc, on behalf on the French Innovative Leukemia Organization (FILO) CLL group

“…Ibrutinib has revolutionized the management of chronic lymphocytic leukemia and is now being increasingly used. Although considered to be less…”
Get full text

Immune response to three doses of mRNA SARS-CoV-2 vaccines in CD19-targeted chimeric antigen receptor T cell immunotherapy recipients by Sesques, Pierre, Bachy, Emmanuel, Ferrant, Emmanuelle, Safar, Violaine, Gossez, Morgane, Morfin-Sherpa, Florence, Venet, Fabienne, Ader, Florence

Get full text

Overall survival benefit of symptom monitoring in real-world patients with chronic lymphocytic leukaemia treated with ibrutinib: a FiLO group study by Ysebaert, Loic, Quinquenel, Anne, Bijou, Fontané, Ferrant, Emmanuelle, Michallet, Anne-Sophie

Get full text

Outcomes of CLL Patients Exposed to Venetoclax+/-R after Ibrutinib in France: The Resist Retrospective Study from the Filo-CLL Group by Ysebaert, Loic, Ferrant, Emmanuelle, Dilhuydy, Marie Sarah, Michallet, Anne-Sophie, Inchiappa, Luca, Guieze, Romain, Tchernonog, Emmanuelle, Cavillon, Ana, Bene, Marie Christine, Fornecker, Luc-Matthieu

“…Background: In chronic lymphocytic leukemia (CLL), despite the fact that Bruton tyrosine kinase inhibitors (BTKi) are increasingly used 1st or 2nd line…”
Get full text

Baseline metabolic tumour volume is an independent prognostic factor in Hodgkin lymphoma by Kanoun, Salim, Rossi, Cédric, Berriolo-Riedinger, Alina, Dygai-Cochet, Inna, Cochet, Alexandre, Humbert, Olivier, Toubeau, Michel, Ferrant, Emmanuelle, Brunotte, François, Casasnovas, René-Olivier

“…Purpose The presence of a bulky tumour at staging in Hodgkin lymphoma (HL) is a predictor of a poor outcome. The total metabolic tumour volume at baseline…”
Get full text

Overall survival of patients with CLL treated with ibrutinib in the first line compared to second-line ibrutinib after chemotherapy/chemoimmunotherapy by Robak, Tadeusz, Doubek, Michael, Ferrant, Emmanuelle, Diels, Joris, Andersone, Liva, Wilbertz, Sabine, Healy, Nollaig C, Neumayr, Lynne, van Sanden, Suzy

“…To evaluate the overall survival (OS) of patients with chronic lymphocytic leukemia (CLL) receiving either ibrutinib monotherapy as a first-line (1L) treatment…”
Get full text

Combined Treatment with Ibrutinib and Anti-CD38 Monoclonal Antibody Daratumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia with TP53 Aberrations: Results of the Filo Phase II Study IDA53 by Aurran-Schleinitz, Therese, Tomowiak, Cécile, Roos-Weil, Damien, Ferrant, Emmanuelle, Mahé, Béatrice, Molina, Lysiane, Ysebaert, Loic, Fornecker, Luc Mathieu, Michallet, Anne-Sophie, Levy, Vincent, Guieze, Romain, Delmer, Alain

Get full text

Prevalence of BTK and PLCG2 mutations in a real-life CLL cohort still on ibrutinib after 3 years: a FILO group study by Quinquenel, Anne, Fornecker, Luc-Matthieu, Letestu, Rémi, Ysebaert, Loïc, Fleury, Carole, Lazarian, Grégory, Dilhuydy, Marie-Sarah, Nollet, Delphine, Guieze, Romain, Feugier, Pierre, Roos-Weil, Damien, Willems, Lise, Michallet, Anne-Sophie, Delmer, Alain, Hormigos, Katia, Levy, Vincent, Cymbalista, Florence, Baran-Marszak, Fanny

“…Mutational analyses performed following acquired ibrutinib resistance have suggested that chronic lymphocytic leukemia (CLL) progression on ibrutinib is linked…”
Get full text

Next-CLL, a New Next-Generation Sequencing–Based Method for Assessment of IGHV Gene Mutational Status in Chronic Lymphoid Leukemia by Bourbon, Estelle, Chabane, Kaddour, Mosnier, Isabelle, Bouvard, Anne, Thonier, Florian, Ferrant, Emmanuelle, Michallet, Anne-Sophie, Poulain, Stéphanie, Hayette, Sandrine, Sujobert, Pierre, Huet, Sarah

“…Current guidelines for patients with chronic lymphocytic leukemia (CLL) recommend mutation status determination of the clonotypic IGHV gene before treatment…”
Get full text

Outcome in Multiple Myeloma Patients Treated in the Era of Modern Therapies Who Were Admitted to Intensive Care: A Retrospective Analysis from a Teaching Hospital between 2014 and 2019 by Gross, Zofia, Idlhaj, Maryam, Karlin, Lionel, Friggeri, Arnaud, Lazareth, Anne, Golfier, Camille, Lequeu, Helene, Bouafia Sauvy, Fadhela, Sesques, Pierre, Safar, Violaine, Ferrant, Emmanuelle, Ghergus, Dana, Maarek, Alizee, Aussedat, Guillaume, Salles, Gilles, Bachy, Emmanuel, Wallet, Florent, Ghesquieres, Herve

Get full text

Flare-up phenomenon or pseudoprogression after CAR T-cell infusion in non-Hodgkin aggressive lymphomas by Sortais, Clara, Cordeil, Stéphanie, Bourbon, Estelle, Idlhaj, Maryam, Ferrant, Emmanuelle, Safar, Violaine, Golfier, Camille, Lazareth, Anne, Bouafia-Sauvy, Fadhela, Tordo, Jérémie, Ghesquières, Hervé, Sesques, Pierre, Bachy, Emmanuel

Get full text